[{"id":"f1481312-1af8-48f0-b565-97281c722271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906031","created_at":"2021-05-28T13:52:32.335Z","updated_at":"2024-07-02T16:36:29.356Z","phase":"Phase 2","brief_title":"Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations","source_id_and_acronym":"NCT04906031","lead_sponsor":"First Affiliated Hospital of Jinan University","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 K139N • TP53 R196* • TP53 R213","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 K139N • TP53 R196* • TP53 R213"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenocta (sodium stibogluconate)"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2021-06-09"},{"id":"0efd0c25-4f85-4b9c-90a2-c13131a34a18","acronym":"","url":"https://clinicaltrials.gov/study/NCT00629200","created_at":"2021-01-18T02:20:21.030Z","updated_at":"2024-07-02T16:37:05.321Z","phase":"Phase 1","brief_title":"Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies","source_id_and_acronym":"NCT00629200","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Lenocta (sodium stibogluconate)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/13/2006","start_date":" 09/13/2006","primary_txt":" Primary completion: 02/10/2010","primary_completion_date":" 02/10/2010","study_txt":" Completion: 02/10/2010","study_completion_date":" 02/10/2010","last_update_posted":"2018-11-15"}]